JPJohn P. A. Puvimanasinghe

John P. A. Puvimanasinghe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John P. A. Puvimanasinghe has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prognosis After Aortic Valve Replacement With the Carpentier-Edwards Pericardial Valve: Use of Microsimulation

    by John P.A. Puvimanasinghe, Johanna J.M. Takkenberg, Marinus J.C. Eijkemans, Ewout W. Steyerberg, Lex A. van Herwerden, Gary L. Grunkemeier, J. Dik F. Habbema, Ad J.J.C. Bogers


  • Open Access

    Comparison of outcomes after aortic valve replacement with a mechanical valve or a bioprosthesis using microsimulation

    by J P A Puvimanasinghe, J J M Takkenberg, M B Edwards, M J C Eijkemans, E W Steyerberg, L A van Herwerden, K M Taylor, G L Grunkemeier, J D F Habbema, A J J C Bogers

    Background: Mechanical valves and bioprostheses are widely used for aortic valve replacement. Though previous randomised studies indicate that there is no important difference in outcome after implantation with either type of valve, knowledge of outcomes after aortic valve replacement is incomplete. Objective: To predict age and sex specific outcomes of patients after aortic valve replacement with bileaflet mechanical valves and stented porcine bioprostheses, and to provide evidence based support for the choice of prosthesis. Methods: Meta-analysis of published results of primary aortic valve replacement with bileaflet mechanical prostheses (nine reports, 4274 patients, and 25 726 patient-years) and stented porcine bioprostheses (13 reports, 9007 patients, and 54 151 patient-years) was used to estimate the annual risks of postoperative valve related events and their outcomes. These estimates were entered into a microsimulation model, which was employed to calculate age and sex specific outcomes after aortic valve replacement. Results: Life expectancy (LE) and event-free life expectancy (EFLE) for a 65 year old man after implantation with a mechanical valve or a bioprosthesis were 10.4 and 10.7 years and 7.7 and 8.4 years, respectively. The lifetime risk of at least one valve related event for a mechanical valve was 48%, and for a bioprosthesis, 44%. For LE and EFLE, the age crossover point between the two valve types was 59 and 60 years, respectively. Conclusions: Meta-analysis based microsimulation provides insight into the long term outcome after aortic valve replacement and suggests that the currently recommended age threshold for implanting a bioprosthesis could be lowered further.


  • Measles Outbreak in Sri Lanka, 1999–2000

    by John P. A. Puvimanasinghe, Carukshi K. Arambepola, Nihal M. R. Abeysinghe, Lalani C. Rajapaksa, Tilak A. Kulatilaka

    A large measles outbreak occurred in Sri Lanka from October 1999 through June 2000 following a period of low incidence. During this period, >15,000 suspected cases were reported to the central Epidemiological Unit of the Department of Health Services. The outbreak was investigated through review of surveillance data for 1999-2000, which were compared with previous surveillance data. Among the clinically confirmed cases, the highest morbidity rate (114/100,000 population) was observed among children /=15 years old, and this percentage had increased over the previous decade. Forty percent of cases had a history of measles vaccination. There were 5 deaths, giving a case-fatality rate of 0.1%. Action taken during the outbreak and plans for future outbreak prevention strategies were also evaluated.


  • Open Access

    Choice of a mechanical valve or a bioprosthesis for AVR: does CABG matter?

    by John P.A. Puvimanasinghe, Johanna J.M. Takkenberg, Marinus J.C. Eijkemans, Ewout W. Steyerberg, Lex A van Herwerden, Gary L. Grunkemeier, J. Dik F. Habbema, Ad J.J.C. Bogers

    Objective: Mechanical valves and bioprostheses are the commonly used devices in aortic valve replacement (AVR). Many patients with valvular disease also require concomitant coronary artery bypass grafting (CABG). We used a microsimulation model to provide insight into the outcomes of patients after AVR with mechanical valves and stented bioprostheses, with and without CABG, and to determine the age-thresholds or age crossover points in outcomes between the two valve types. Methods: We conducted a meta-analysis of published results after primary AVR with mechanical prostheses (nine reports, 4274 patients, 25,726 patient-years) and stented porcine bioprostheses (13 reports, 9007 patients, 54,151 patient-years) to estimate risks of valve-related events. A hazard ratio of 1.3 was used to incorporate the effect of CABG on long-term survival. Estimates were entered into a microsimulation model, which was then used to predict the outcomes of patients after AVR, with and without CABG. The model calculations were validated using a large data set from Portland, USA. Results: For a 65-year-old male without CABG, the life expectancy (LE) was 11.2 and 11.6 years and the event-free life expectancy (EFLE) was 8.2 and 8.9 years, respectively, after implantation with mechanical valves and bioprostheses. The lifetime risk of at least one valve-related event was 51 and 47%, respectively. The age crossover point between the two valve types, considering the above outcome parameters, was 59, 60 and 63 years, respectively. CABG reduced LE and consequently EFLE and lifetime risk of an event, but only minimally influenced the patient age crossover points. The model calculations showed good agreement with the Portland data. Conclusions: The currently recommended patient age for using a bioprosthesis (65 years) could be lowered further, irrespective of concomitant CABG. The trade-off between the reduced risks of bioprosthetic failure and of hemorrhage in mechanical valves, resulting from a lower LE, minimized the effect of CABG on the age crossover points between the two valve types.


  • Open Access

    Prognosis after aortic valve replacement with St. Jude Medical bileaflet prostheses: impact on outcome of varying thromboembolic and bleeding hazards

    by J.J.M. Takkenberg, J.P.A. Puvimanasinghe, L.A. van Herwerden, E.W. Steyerberg, M.J.C. Eijkemans, J.D.F Habbema, A.J.J.C. Bogers

    Aims Prognosis after aortic valve replacement (AVR) with mechanical prostheses depends on multiple inter-related factors. Investigation into these factors is complicated by limited knowledge on outcome after AVR and by the varying therapeutic ranges of International Normalized Ratio employed worldwide. Meta-analysis was combined with microsimulation to calculate evidence-based, age-specific outcomes after AVR with St. Jude Medical (SJM) prostheses (St. Jude Medical, Inc., St. Paul, MN, U.S.A.). Method and results Eight studies were included in a meta-analysis of published results of primary isolated AVR with SJM prostheses (2986 patients, 16,163 patient-years) in order to estimate the hazard of postoperative valve-related events. Using microsimulation, calculated life expectancy and event-free life expectancy were 22 and 16 years in males aged 35 years, and 7 and 5 years in males aged 75 years, respectively. Calculated lifetime risks for thromboembolic and bleeding events were 22% and 15% in males aged 35 years, and 7% and 37% in males aged 75 years, respectively. Varying thromboembolic and bleeding hazards resulted in considerable shifts in lifetime risks and deaths associated with these events. Conclusion Meta-analysis combined with microsimulation is a powerful tool with which to calculate reliable estimates of long-term prognosis, and allows detailed insight into the occurrence of valve-related events. Thromboembolism and bleeding occur frequently after AVR with mechanical prostheses and have an important impact on survival. Optimal control of International Normalized Ratio is therefore of utmost importance.